While most self-expanding transcatheter valves are repositionable, only one fully retrievable valve is currently available. The Meridian valve is a new self-expanding valve with full retrievability properties. The objective of our study was to evaluate the early feasibility, preliminary safety, and efficacy of transcatheter aortic valve replacement with the HLT Meridian valve (HLT, Inc).
MAPLE GROVE, Minn. (August 28, 2019) – HLT, Inc., a medical device company developing leading edge transcatheter aortic valve replacement (TAVR) therapy, today announced the addition of David R. Elizondo as Senior Vice President Research and Development and General Manager. In his new role, Elizondo will lead the research and development of HLT’s Meridian ® valve platform and work closely with Bradley Fox, President and CEO, on HLT’s strategic business objectives and milestones in collaboration with HLT’s parent company, Bracco Group.
“We are thrilled to have David Elizondo join the HLT team,” said Bradley Fox, President and Chief Executive Officer, HLT and ACIST Medical Systems. “David brings an impressive record of achievement in cardiovascular implant technologies to HLT. His demonstrated ability to lead both cross-functional teams and complex technology programs will be invaluable in our mission to provide TAVR patients with a new level of flexibility and hemodynamic performance.”
Prior to joining HLT, Mr. Elizondo lead Global Research and Development and Project Management Activities for Men’s Health, Women’s Health, Endourology, and Specialty Interventions at Coloplast Urology Division in the US and Europe. Previously, Elizondo was Chief Operating Officer, Direct Flow Medical, Inc., where he was responsible for all Research and Development, Operations, Manufacturing, and facilities activities. While at Direct Flow, Elizondo successfully led products and technologies through various internal and external activities from concept to commercialization in the United States and Europe.
“This is a very exciting time to join HLT,” said Elizondo. “HLT is poised to bring new and enhanced products to our patients. I am eager to work with a very dedicated staff and the leadership team to lead HLT into the future.”
Elizondo has over 25 years of medical device and business expertise through a range of different career experiences. He served as Vice President of Research, Development, and Clinical Affairs at ATS Medical, Inc., and has held various leadership positions within the United States and South America in Technology, Research, and Business Development while at St. Jude Medical, Inc. and Boston Scientific Corp. Elizondo holds a Bachelor’s of Science degree in Biomedical Engineering from the Milwaukee School of Engineering (Wisconsin) and a Master’s of Science degree in Biomedical Engineering from the University of Iowa (Iowa). He has also completed advanced technology and management studies at both the University of Iowa and St.
Thomas University (Minnesota).
HLT, Inc. is a clinical stage medical device company developing a novel transcatheter valve therapy designed to provide physicians with procedural flexibility. The company is committed to driving heart valve therapy forward with next-generation technology. The system is designed to offer physicians a fully retrievable valve with a low profile and that is designed for durability. With global headquarters in Maple Grove, Minnesota, USA, HLT employs over 100 highly experienced healthcare and device industry professionals working in a creative, collaborative and entrepreneurial environment.
HLT also works alongside its sister company, ACIST Medical Systems, a pioneer and market leader of advanced contrast delivery and imaging systems for interventional cardiology. Both are part of the Bracco Group, an Italy-based, multinational healthcare company and leader in diagnostic imaging operating in over 100 countries worldwide with revenues exceeding €1.3B. Bracco invests a significant amount of its resources in research and innovation across its portfolio of companies to improve patient outcomes and optimize treatment procedures.
To learn more about HLT, visit www.hltmedical.com.
Investigational device outside the United States. Not available for sale in any geography.